Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Simeonov, Anton ^a   Kulkarni, Avanti ^b   Dorjsuren, Dorjbal ^a   Jadhav, Ajit ^a   Shen, Min ^a   McNeill, Daniel R ^b   Austin, Christopher P ^a   Wilson III, David M ^b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APYRIMIDINIC ENDONUCLEASE 1; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; MESYLIC ACID METHYL ESTER; UNCLASSIFIED DRUG; APEX1 PROTEIN, HUMAN; CIBACRON BLUE F 3GA; COLORING AGENT; DEOXYRIBONUCLEASE IV; DNA; FLAVONOID; FLUOROURACIL; MYRICETIN; RECOMBINANT PROTEIN; TRIAZINE DERIVATIVE;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA EXTRACTION; EXCISION REPAIR; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INACTIVATION; GENE STRUCTURE; GENETIC SCREENING; GENOTOXICITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PROTEIN DETERMINATION; REACTION TIME; STRUCTURE ANALYSIS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DNA DAMAGE; DRUG ANTAGONISM; ENZYME ACTIVE SITE; ENZYMOLOGY; ESCHERICHIA COLI; HELA CELL; METABOLISM; PHYSIOLOGY;

CATALYTIC DOMAIN; CELL LINE; COLORING AGENTS; DEOXYRIBONUCLEASE IV (PHAGE T4-INDUCED); DNA; DNA DAMAGE; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; ESCHERICHIA COLI; FLAVONOIDS; FLUOROURACIL; HELA CELLS; HUMANS; MODELS, MOLECULAR; RECOMBINANT PROTEINS; TRIAZINES;

EID: 66749155332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005740     Document Type: Article

References (56)

1. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nature Reviews Cancer 8: 193-204.
2. Wyatt MD, Pittman DL (2006) Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks. Chemical Research in Toxicology 19: 1580-1594.
3. Zaremba T, Curtin NJ (2007) PARP inhibitor development for systemic cancer targeting. Current Medicinal Chemistry - Anti-Cancer Agents 7: 515-523.
4. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Journal of Clinical Oncology 26: 3785-3790.
5. Wilson DM 3rd, Bohr VA (2007) The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair 6: 544-559.
6. Demple B, Sung JS (2005) Molecular and biological roles of Ape1 protein in mammalian base excision repair. DNA Repair (Amst) 4: 1442-1449.
7. Wilson DM 3rd, Barsky D (2001) The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mutat Res 485: 283-307.
8. Fung H, Demple B (2005) A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. Mol Cell 17: 463-470.
9. Izumi T, Brown DB, Naidu CV, Bhakat KK, Macinnes MA, et al. (2005) Two essential but distinct functions of the mammalian abasic endonuclease. Proc Natl Acad Sci U S A 102: 5739-5743.
10. Fishel ML, Kelley MR (2007) The DNA base excision repair protein Ape1/ Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 28: 375-395.
11. McNeill DR, Wilson DM 3rd (2007) A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol Cancer Res 5: 61-70.
12. Wyatt MD, Wilson DM 3rd (2009) Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 66: 788-799.
13. Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, et al. (2005) Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res 33: 4711-4724.
14. Bapat A, Fishel ML, Kelley MR (2009) Going Ape as an Approach to Cancer Therapeutics. Antioxidants & Redox Signaling epub ahead of print.
15. Seiple LA, Cardellina JH 2nd, Akee R, Stivers JT (2008) Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids. Mol Pharmacol 73: 669-677.
16. De Wolff FA (1995) Antimony and health. BMJ 310: 1216-1217.
17. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, et al. (2006) Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Nat Acad Sci USA 103: 11473-11478.
18. Yasgar A, Shinn P, Michael S, Zheng W, Jadhav A, et al. (2008) Compound Management for Quantitative High-Throughput Screening. J Assoc Lab Automat 13: 79-89.
19. Erzberger JP, Barsky D, Scharer OD, Colvin ME, Wilson DM 3rd (1998) Elements in abasic site recognition by the major human and Escherichia coli apurinic/apyrimidinic endonucleases. Nucleic Acids Research 26: 2771-2778.
20. Wilson DM 3rd, Takeshita M, Grollman AP, Demple B (1995) Incision activity of human apurinic endonuclease (Ape) at abasic site analogs in DNA. Journal of Biological Chemistry 270: 16002-16007.
21. Wilson DM 3rd (2005) Ape1 abasic endonuclease activity is regulated by magnesium and potassium concentrations and is robust on alternative DNA structures. J Mol Biol 345: 1003-1014.
22. Tse WC, Boger DL (2004) A fluorescent intercalator displacement assay for establishing DNA binding selectivity and affinity. Accounts of Chemical Research 37: 61-69.
23. Paz-Elizur T, Elinger D, Leitner-Dagan Y, Blumenstein S, Krupsky M, et al. (2007) Development of an enzymatic DNA repair assay for molecular epidemiology studies: distribution of OGG activity in healthy individuals. DNA Repair 6: 45-60.
24. Hallgren TA (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comp Chem 17: 490-519.
25. Case DA, et al. (2002) Amber 7. San Francisco: University of California.
26. Cook RM, Lyttle M, Dick D (2006) Dark quenchers for donor-acceptor energy transfer. In: PTO U, ed. USA: Biosearch Technologies, Inc.
27. Simeonov A, Jadhav A, Thomas C, Wang Y, Huang R, et al. (2008) Fluorescent Spectroscopic Profiling of Compound Libraries. J Med Chem 51: 2363-2371.
28. Berquist BR, McNeill DR, Wilson DM 3rd (2008) Characterization of abasic endonuclease activity of human Ape1 on alternative substrates, as well as effects of ATP and sequence context on AP site incision. Journal of Molecular Biology 379: 17-27.
29. Sokhansanj BA, Rodrigue GR, Fitch JP, Wilson DM 3rd (2002) A quantitative model of human DNA base excision repair. I. Mechanistic insights. Nucleic Acids Research 30: 1817-1825.
30. Michael S, Auld D, Klumpp C, Jadhav A, Zheng W, et al. (2008) A Robotic Platform for Quantitative High-Throughput Screening. Assay Drug Dev Technol 6: 637-657.
31. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
32. Eastwood BJ, Farmen MW, Iversen PW, Craft TJ, Smallwood JK, et al. (2006) The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies. J Biomol Screen 11: 253-261.
33. Perez-Ruiz T, Martinez-Lozano C, Sanz A, Bravo E (2001) Simultaneous determination of doxorubicin, daunorubicin, and idarubicin by capillary electrophoresis with laser-induced fluorescence detection. Electrophoresis 22: 134-138.
34. Imoto M, Kakeya H, Sawa T, Chigusa H, Hamada M, et al. (1993) Dephostatin, a novel proteintyrosine phosphatase inhibitor produced by Streptomyces. J Antibiotics (Tokyo) 45: 1342-1346.
35. Kremer L, Douglas JD, Baulard AR, Morehouse C, Guy MR, et al. (2000) Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. Journal of Biological Chemistry 275: 16857-16864.
36. Mol CD, Hosfield DJ, Tainer JA (2000) Abasic site recognition by two apurinic/apyrimidinic endonuclease families in DNA base excision repair: the 3′ ends justify the means. Mutat Res 460: 211-229.
37. Gonzalez RG, Haxo RS, Schleich T (1980) Mechanism of action of polymeric aurintricarboxylic acid, a potent inhibitor of protein-nucleic acid interactions. Biochemistry 19: 4299-4303.
38. Chen DS, Herman T, Demple B (1991) Two distinct human DNA diesterases that hydrolyze 3′-blocking deoxyribose fragments from oxidized DNA. Nucleic Acids Research 19: 5907-5914.
39. McNeill DR, Narayana A,Wong HK, Wilson DM3rd (2004) Inhibition of Ape1 nuclease activity by lead, iron, and cadmium. Environ Health Perspect 112: 799-804.
40. Nakamura J, Walker VE, Upton PB, Chiang SY, Kow YW, et al. (1998) Highly sensitive apurinic/apyrimidinic site assay can detect spontaneous and chemically induced depurination under physiological conditions. Cancer Research 58: 222-225.
41. Horton JK, Wilson SH (2007) Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency. DNA Repair 6: 530-543.
42. Benchokroun Y, Couprie J, Larsen AK (1995) Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Biochemical Pharmacology 49: 305-313.
43. Bina-Stein M, Tritton TR (1976) Aurintricarboxylic acid is a nonspecific enzyme inhibitor. Molecular Pharmacology 12: 191-193.
44. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, et al. (2007) High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3: 466-479.
45. Zawahir Z, Dayam R, Deng J, Pereira C, Neamati N (2009) Pharmacophore Guided Discovery of Small-Molecule Human Apurinic/Apyrimidinic Endonuclease 1 Inhibitors. Journal of Medicinal Chemistry 52: 20-32.
46. Burton SJ, McLoughlin SB, Stead CV, Lowe CR (1988) Design and applications of biomimetic anthraquinone dyes: I. Synthesis and characterisation of terminal ring isomers of C.I. Reactive Blue 2. Journal of Chromatography A 435: 127-137.
47. Bo X, Fischer B, Maillard M, Jacobson KA, Burnstock G (1994) Comparative studies on the affinities of ATP derivatives for P2x-purinoceptors in rat urinary bladder. British Journal of Pharmacology 112: 1151-1159.
48. Brown J, Brown CA (2002) Evaluation of reactive blue 2 derivatives as selective antagonists for P2Y receptors. Vascular Pharmacology 39: 309-315.
49. Mol CD, Kuo CF, Thayer MM, Cunningham RP, Tainer JA (1995) Structure and function of the multifunctional DNA-repair enzyme exonuclease III. Nature 374: 381-386.
50. Jonsson G, Sachs C (1973) Pharmacological modifications of the 6-hydroxydopa induced degeneration of central noradrenaline neurons. Biochemical Pharmacology 22: 1709-1716.
51. Hakkinen SH, Karenlampi SO, Heinonen IM, Mykkanen HM, Torronen AR (1999) Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. Journal of Agricultural & Food Chemistry 47: 2274-2279.
52. Ong KC, Khoo HE (1997) Biological effects of myricetin. General Pharmacology 29: 121-126.
53. Uyeta M, Taue S, Mazaki M (1981) Mutagenicity of hydrolysates of tea infusions. Mutation Research 88: 233-240.
54. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, et al. (2006) Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Research 66: 4410-4418.
55. Lee KW, Kang NJ, Rogozin EA, Kim H-G, Cho YY, et al. (2007) Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 28: 1918-1927.
56. Das M, Khan WA, Asokan P, Bickers DR, Mukhtar H (1987) Inhibition of polycyclic aromatic hydrocarbon-DNA adduct formation in epidermis and lungs of SENCAR mice by naturally occurring plant phenols. Cancer Research 47: 767-773.